Show simple item record

Entendiendo las terapias actuales en melanoma metastásico

UNDERSTANDING CURRENT THERAPIES IN METASTATIC MELANOMA

dc.contributorPontificia Universidad Católica de Chilees-ES
dc.contributoren-US
dc.creatorRodríguez, Rocío; Pontificia Universidad Católica de Chile
dc.creatorParra, Angela; Pontificia Universidad Católica de Chile
dc.creatorGonzález, Sergio; Pontificia Universidad Católica de Chile
dc.creatorMolgó, Montserrat; Pontificia Universidad Católica de Chile
dc.creatorDroppelmann, Nicolás; Pontificia Universidad Católica de Chile
dc.creatorAcevedo C, Francisco; Pontificia Universidad Católica de Chile
dc.creatorPeña, José; Pontificia Universidad Católica de Chile
dc.creatorUribe, Pablo; Pontificia Universidad Católica de Chile
dc.date2016-11-25
dc.date.accessioned2019-11-11T18:26:44Z
dc.date.available2019-11-11T18:26:44Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/4468
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/110800
dc.descriptionCutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PDL-1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.es-ES
dc.descriptionCutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PDL-1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.en-US
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/4468/2584
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20014
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20015
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20016
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20017
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20018
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20019
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20020
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20021
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20022
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20023
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20024
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20025
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20026
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20027
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20028
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20029
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/20222
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/22223
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/22224
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/22400
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/4468/26902
dc.sourceRevista Médica de Chile; Vol. 144, núm. 11 (2016): NOVIEMBRE 2016es-ES
dc.source0034-9887
dc.subjectCTLA-4 Antigen; Melanoma; Molecular Targeted Therapy; Pembrolizumab; Programmed Cell Death 1 Receptores-ES
dc.subjectCTLA-4 Antigen; Melanoma; Molecular Targeted Therapy; Pembrolizumab; Programmed Cell Death 1 Receptoren-US
dc.titleEntendiendo las terapias actuales en melanoma metastásicoes-ES
dc.titleUNDERSTANDING CURRENT THERAPIES IN METASTATIC MELANOMAen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record